Sarepta Therapeutics (SRPT) Halted Ahead of FDA AdCom

Sarepta Therapeutics (NASDAQ: SRPT) has been halted ahead of today FDA AdCom to review the New Drug Application (NDA) for eteplirsen.

After plunging last Thursday on negative-biased FDA briefing documents, shares surged on Friday on positive draft questions.

You May Also Be Interested In

• Sixth Street renews bid for Brighthouse Financial amid rival deal delays
• Goldman Sachs in talks to buy $37B credit first Palmer Square - Bloomberg
• Trump: Putin is willing to meet to end war